Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.24
SNSS's Cash to Debt is ranked lower than
63% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. SNSS: 5.24 )
Ranked among companies with meaningful Cash to Debt only.
SNSS' s 10-Year Cash to Debt Range
Min: 2.18  Med: 23.18 Max: No Debt
Current: 5.24
Equity to Asset 0.41
SNSS's Equity to Asset is ranked lower than
77% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. SNSS: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
SNSS' s 10-Year Equity to Asset Range
Min: -3.31  Med: 0.60 Max: 0.89
Current: 0.41
-3.31
0.89
F-Score: 2
Z-Score: -18.35
M-Score: -4.06
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -976.22
SNSS's Operating margin (%) is ranked lower than
79% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. SNSS: -976.22 )
Ranked among companies with meaningful Operating margin (%) only.
SNSS' s 10-Year Operating margin (%) Range
Min: -64863.64  Med: -469.38 Max: -169.03
Current: -976.22
-64863.64
-169.03
Net-margin (%) -817.70
SNSS's Net-margin (%) is ranked lower than
78% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. SNSS: -817.70 )
Ranked among companies with meaningful Net-margin (%) only.
SNSS' s 10-Year Net-margin (%) Range
Min: -74506.06  Med: -422.55 Max: -166.44
Current: -817.7
-74506.06
-166.44
ROE (%) -247.69
SNSS's ROE (%) is ranked lower than
93% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. SNSS: -247.69 )
Ranked among companies with meaningful ROE (%) only.
SNSS' s 10-Year ROE (%) Range
Min: -1585.52  Med: -133.15 Max: -57.33
Current: -247.69
-1585.52
-57.33
ROA (%) -71.36
SNSS's ROA (%) is ranked lower than
79% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. SNSS: -71.36 )
Ranked among companies with meaningful ROA (%) only.
SNSS' s 10-Year ROA (%) Range
Min: -448.13  Med: -63.27 Max: -39.99
Current: -71.36
-448.13
-39.99
ROC (Joel Greenblatt) (%) -89470.30
SNSS's ROC (Joel Greenblatt) (%) is ranked lower than
98% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. SNSS: -89470.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SNSS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -127024.62  Med: -2975.57 Max: -460.2
Current: -89470.3
-127024.62
-460.2
Revenue Growth (3Y)(%) -6.50
SNSS's Revenue Growth (3Y)(%) is ranked lower than
57% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. SNSS: -6.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SNSS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -51.30 Max: 74.5
Current: -6.5
0
74.5
EBITDA Growth (3Y)(%) 15.90
SNSS's EBITDA Growth (3Y)(%) is ranked higher than
73% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. SNSS: 15.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SNSS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -59.5  Med: -35.70 Max: 15.9
Current: 15.9
-59.5
15.9
EPS Growth (3Y)(%) 18.70
SNSS's EPS Growth (3Y)(%) is ranked higher than
76% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. SNSS: 18.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SNSS' s 10-Year EPS Growth (3Y)(%) Range
Min: -60.4  Med: -48.40 Max: 20.5
Current: 18.7
-60.4
20.5
» SNSS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

SNSS Guru Trades in Q2 2014

Steven Cohen 468,500 sh (unchged)
Jim Simons 22,886 sh (-1.41%)
First Eagle Investment 200,000 sh (-8.91%)
» More
Q3 2014

SNSS Guru Trades in Q3 2014

Jim Simons Sold Out
Steven Cohen Sold Out
First Eagle Investment Sold Out
» More
Q4 2014

SNSS Guru Trades in Q4 2014

Paul Tudor Jones 17,516 sh (New)
First Eagle Investment 1,414,276 sh (New)
» More
Q1 2015

SNSS Guru Trades in Q1 2015

Paul Tudor Jones Sold Out
First Eagle Investment 587,976 sh (-58.43%)
» More
» Details

Insider Trades

Latest Guru Trades with SNSS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 6.62
SNSS's P/B is ranked higher than
53% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. SNSS: 6.62 )
Ranked among companies with meaningful P/B only.
SNSS' s 10-Year P/B Range
Min: 1.01  Med: 2.66 Max: 297.5
Current: 6.62
1.01
297.5
P/S 18.91
SNSS's P/S is ranked lower than
57% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. SNSS: 18.91 )
Ranked among companies with meaningful P/S only.
SNSS' s 10-Year P/S Range
Min: 0.9  Med: 9.81 Max: 157.25
Current: 18.91
0.9
157.25
Current Ratio 2.59
SNSS's Current Ratio is ranked lower than
68% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. SNSS: 2.59 )
Ranked among companies with meaningful Current Ratio only.
SNSS' s 10-Year Current Ratio Range
Min: 0.71  Med: 2.97 Max: 12.17
Current: 2.59
0.71
12.17
Quick Ratio 2.59
SNSS's Quick Ratio is ranked lower than
64% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. SNSS: 2.59 )
Ranked among companies with meaningful Quick Ratio only.
SNSS' s 10-Year Quick Ratio Range
Min: 0.71  Med: 2.97 Max: 12.17
Current: 2.59
0.71
12.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.00
SNSS's Price/Net Cash is ranked higher than
72% of the 451 Companies
in the Global Biotechnology industry.

( Industry Median: 8.40 vs. SNSS: 7.00 )
Ranked among companies with meaningful Price/Net Cash only.
SNSS' s 10-Year Price/Net Cash Range
Min: 1.68  Med: 3.23 Max: 178.5
Current: 7
1.68
178.5
Price/Net Current Asset Value 6.39
SNSS's Price/Net Current Asset Value is ranked higher than
73% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. SNSS: 6.39 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SNSS' s 10-Year Price/Net Current Asset Value Range
Min: 1.62  Med: 2.89 Max: 273.5
Current: 6.39
1.62
273.5
Price/Tangible Book 6.39
SNSS's Price/Tangible Book is ranked higher than
61% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. SNSS: 6.39 )
Ranked among companies with meaningful Price/Tangible Book only.
SNSS' s 10-Year Price/Tangible Book Range
Min: 1.6  Med: 2.70 Max: 273.5
Current: 6.39
1.6
273.5
Price/Median PS Value 2.49
SNSS's Price/Median PS Value is ranked lower than
65% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. SNSS: 2.49 )
Ranked among companies with meaningful Price/Median PS Value only.
SNSS' s 10-Year Price/Median PS Value Range
Min: 0.1  Med: 1.08 Max: 14.44
Current: 2.49
0.1
14.44
Earnings Yield (Greenblatt) (%) -46.19
SNSS's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SNSS: -46.19 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SNSS' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -81.97  Med: 45.80 Max: 16670.9
Current: -46.19
-81.97
16670.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:RYIN.Germany,
Sunesis Pharmaceuticals Inc was incorporated in the state of Delaware on February 10, 1998. It is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. It currently focuses on the development of vosaroxin for the treatment of acute myeloid leukemia, or AML. Vosaroxin is an anti-cancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. In October 2014, the Company announced the results of a Phase 3, multi-national, randomized, double-blind, placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML, or the VALOR trial. The VALOR trial, which enrolled 711 adult patients, was designed to evaluate the effect of vosaroxin in combination with cytarabine, most commonly used chemotherapy in AML, on overall survival as compared to placebo in combination with cytarabine, and was conducted at 124 study sites in the U.S., Canada, Europe, South Korea, Australia and New Zealand. It faces competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching, developing and marketing products designed to address the treatment of cancer, including AML and ovarian cancer. In addition to regulations in the United States, the Company is subject to foreign regulations governing clinical trials and commercial sales and distribution of vosaroxin or its future drug candidates, if any.
» More Articles for SNSS

Headlines

Articles On GuruFocus.com
ciazek stock Mar 28 2015 
comment on SNSS Mar 02 2013 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 
Weekly CFO Buys Highlight: SNSS, INUV, CEP, CMTL, SURW Oct 09 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 13 2010 
cooldecency99 note on SNSS May 01 2010 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 
Most Trade Guru Stocks: Citigroup Inc., Bank of America Corp., Alcoa Inc., Sunesis Pharmaceuticals Dec 12 2009 
Sunesis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 16 2009 

More From Other Websites
SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 30 2015
7:52 am Sunesis Pharma reports EPS in-line, misses on revs Jul 30 2015
Sunesis reports 2Q loss Jul 30 2015
Sunesis reports 2Q loss Jul 30 2015
Sunesis Pharmaceuticals Reports Second Quarter 2015 Financial Results and Recent Highlights Jul 30 2015
Sunesis Pharmaceuticals Reports Second Quarter 2015 Financial Results and Recent Highlights Jul 30 2015
Sunesis Pharmaceuticals (SNSS) Jumps: Stock Gains 9.5% - Tale of the Tape Jul 28 2015
GPM Announces Investigation of Sunesis Pharmaceuticals, Inc. Jul 27 2015
EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against Sunesis... Jul 24 2015
IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Claims Against Sunesis... Jul 24 2015
Investigation of Sunesis Pharmaceuticals, Inc. Announced by The Law Offices of Howard G. Smith Jul 24 2015
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation of Sunesis Pharmaceuticals, Inc.... Jul 24 2015
Shareholder Alert: AF&T Announces That It Has Been Retained to Investigate Claims on Behalf of... Jul 24 2015
Is This the End of Sunesis? Jul 24 2015
Top Analyst Upgrades and Downgrades: Amazon, GM, SolarCity, Sunesis, United Continental, Disney,... Jul 24 2015
Sunesis Pharma downgraded by ROTH Capital and Cantor Fitzgerald Jul 24 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis... Jul 23 2015
Sunesis tumbles as FDA says it won't approve cancer drug Jul 23 2015
Sunesis tumbles as FDA says it won't approve cancer drug Jul 23 2015
Sunesis Pharmaceuticals Announces Regulatory Update Jul 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK